BioMimetix Announces Acceptance of Late-Breaking Abstract and Oral Presentation of BMX-001 Clinical Data at the 2023 Society for Neuro-Oncology Annual Meeting

BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced that data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG), has been selected as a late breaking oral presentation at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting taking place on November 15-19, 2023 in Vancouver, Canada.

In line with conference publication guidelines, Late-Breaking Abstracts will be made public at 7:00 a.m. PT on the first day of the meeting, Friday, November 17, 2023 and at https://academic.oup.com/neuro-oncology/supplements.

Details of the oral presentation are as follows:

Title: Results of BMX-HGG study: a multi-institutional, randomized phase 2 clinical trial of concurrent chemoradiation with or without BMX-001 in patients with newly diagnosed high-grade glioma
Abstract Number: LTBK-09
Date and Time: Friday, November 17, 2023, from 9:05 ? 9:15 a.m. PT
Session: Plenary I, Exhibit Hall C
Presenter: Katherine Peters, M.D., Duke University Medical Center

About BioMimetix JV, LLC

BioMimetix JV, LLC is a clinical-stage biotechnology company developing a novel platform drug class, metalloporphyrins, that enhances the effectiveness and safety of chemoradiation for the treatment of cancer patients. The Company's robust clinical pipeline spanning oncology and dermatology indications are supported by demonstrated clinical efficiency in ongoing clinical studies and extensive preclinical data in solid tumors as well as inflammatory skin diseases. BioMimetix's lead candidate, BMX-001, is currently being evaluated for a Phase 3 pivotal trial in high-grade glioma.